Research Article

Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil in Head and Neck Squamous Cell Carcinoma In Vitro

Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune

Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Correspondence should be addressed to Ryuji Yasumatsu, yasuryuj@qent.med.kyushu-u.ac.jp

Received 26 October 2011; Accepted 29 January 2012

Academic Editor: Dirk Rades

Copyright © 2012 Ryuji Yasumatsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

5-Fluorouracil (5-FU) is a widely used drug in head and neck squamous cell carcinoma (HNSCC). In the anabolic pathway of 5-FU, the first step in activation of the drug is phosphorylation of 5-FU by orotate phosphoribosyltransferase (OPRT), which directly metabolizes 5-FU to 5-fluorouridine monophosphate (FUMP) in the presence of 5-phosphoribosyl-1-pyrophosphate. To date, OPRT expression in the tumors has been related to the clinical response or survival of cancer patients receiving 5-FU-based chemotherapy. In this study, we examined whether OPRT expression correlates with the chemosensitivity to 5-FU and cell proliferation in HNSCC. We constitutively expressed an OPRT cDNA in an HNSCC cell line. The effects of OPRT expression on in vitro cell growth and 5-FU cytotoxicity were examined. OPRT transfection increases the cytotoxicity of 5-FU without affecting cell proliferation of HNSCC cells in vitro. These results indicate that OPRT expression plays an important role in the sensitivity of HNSCC to 5-FU chemotherapy.

1. Introduction

5-Fluorouracil (5-FU) has been used most frequently for treating head and neck squamous cell carcinoma (HNSCC) in a form of single agent or in combination with cisplatin [1] and the drug of choice for systemic therapy in colorectal cancer [2]. However, nowadays 5-FU resistance during the course of treatment has become common, which is an important cause of failure for cancer therapies [3].

It has been reported that response rate of 5-FU and its derivatives are due to interindividual difference in the enzyme activities for anabolism and catabolism. In the anabolic pathway of 5-FU, the first step in activation of the drug is phosphorylation of 5-FU by orotate phosphoribosyltransferase (OPRT), which directly metabolizes 5-FU to 5-fluorouridine monophosphate (FUMP) in the presence of 5-phosphoribosyl-1-pyrophosphate [4]. This step is the most important mechanism of 5-FU activation. To date, OPRT expression in the tumors has been related to the clinical response or survival of cancer patients receiving 5-FU-based chemotherapy [5, 6]. However, no study has confirmed directly whether the regulation of intratumoral OPRT expression level affects the efficacy of 5-FU and the cell activity in HNSCC. We therefore investigated whether overexpression of the OPRT enhances sensitivity to 5-FU.

In this study, to assess the role of OPRT in the biological regulation of HNSCC, we constitutively expressed the OPRT complementary DNA (cDNA) in HNSCC cell line. The effect of OPRT on in vitro cell growth and 5-FU cytotoxicity was examined.

2. Materials and Methods

2.1. Cell Line. The human head and neck squamous cell carcinoma cell line, YCU-H, which was generously provided by Dr. M. Tsukuda, was cultured in RPMI 1640 medium and supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin 1000 IU/mL (Invitrogen, Carlsbad, CA, USA). Cells were maintained in a humidified incubator at 37°C under 5% CO2.
2.2. Vector Construction and Transfection. Full-length human OPRT cDNA (kindly provided by Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) that contained the entire coding sequence was subcloned in its sense orientation into Eco RI-Kpn I sites of the expression vector pTARGET. Human YCU-H cells were stably transfected with the pTARGET-OPRT plasmid and the pTARGET vector control plasmid via liposome-mediated transfection using Lipofectamine 2000 (Invitrogen), according to the conditions described by the supplier. Forty-eight hours after transfection, transduced cells were selected in complete medium containing 500 μg/mL Geneticin (Invitrogen) for 2 to 3 weeks. After selection, single independent clones were randomly isolated using cloning rings, and each clone was plated separately.

2.3. Western Blot Analysis of Cultured Cells. Western blot analyses were performed as reported previously [7, 8] to detect the OPRT expression in the YCU-H cell line. Total cellular protein was extracted and quantified using the M-Per Mammalian Protein Extracted Reagent and “Coomassie” Protein Assay Reagent Kit (Pierce, Rockford, IL). Equal amounts (10 μg) of cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked for 1 h with 5% nonfat dry milk in PBS and then incubated with the purified polyclonal antibody against OPRT (kindly provided by Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) or an anti-β-actin antibody (Sigma Chemical Company, St. Louis, MO, USA) for loading control for 1 h at 37°C. The membranes were then incubated with the HRP-conjugated goat anti-rabbit IgG secondary antibody for 1 h at room temperature, followed by the detection with the enhanced chemiluminescence (ECL) system (Amersham International, Buckinghamshire, UK).

2.4. In Vitro Proliferation Assays. Transfected clone and vector control clone cells (1 × 10^4 cells/dish) were seeded onto 35 mm dishes in RPMI 1640 medium plus 10% FBS. The number of the cells was counted every 48 hours for 8 subsequent days, in triplicate assays, using a Coulter Counter (Beckman Coulter, Fullerton, CA, USA). The mean values were used to generate growth curves.

2.5. Drug Sensitivity Assay. Transfected cells and control cells were plated in 96-well plates at a density of 10^4 cells/well and further incubated for 24 h. The medium was then removed and replaced with fresh medium containing 5-FU (kindly provided by Kyowa Hakko Co. Ltd.) for another 48 h. Then, 10 μL sterile MTT dye (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 5 mg/mL; Sigma) was added to the culture medium to a final concentration of 0.5 mg/mL and incubated at 37°C for 2 h. After that, the formazan crystals were solubilized with 100 μL of dimethylsulfoxide (DMSO) for 10 min. Spectrometric absorbance at 550 nm was measured with microplate reader. The IC_{50} value was determined by the dose of drug that caused 50% cell viability.

2.6. Statistical Analysis. Statistical analyses were performed using the Mann-Whitney U test. The Kaplan-Meier method was used for analysis of survival data. The significance of differences of survival plots was analyzed by the log-rank test. Differences with a P value <0.05 were considered to be significant.

3. Results

3.1. Transfection of OPRT cDNA in YCU-H Human Head and Neck SCC Cell Line. Four independent clones were selected after 2 to 3 weeks of growth in medium supplemented with Geneticin (500 μg/mL). Representative clone, H-OPRT, was selected for use in subsequent experiments. The levels of OPRT of the selected clone and YCU-H cells are illustrated in Figure 1. The level of OPRT protein was increased 35 times in the H-OPRT cells compared to control cells, respectively.

3.2. In Vitro Growth of the OPRT Overexpressing Cell Line. When grown in 10% fetal bovine serum medium, the vector control cell lines and OPRT transfected cell line showed similar doubling times. There were no significant differences in in vitro growth between OPRT overexpressing clone and control clones (Figure 2).

3.3. Correlation between the Level of OPRT Expression in HNSCC Cells and Their Sensitivity to 5-FU. Cell cytotoxic assays were performed using MTT assay to examine whether the transfected OPRT cDNA increased 5-FU sensitivity in the OPRT overexpressing cells. The increased sensitivity of the OPRT transfected cells to 5-FU was observed in H-OPRT cells. The 50% growth inhibitory (IC_{50}) value to 5-FU in H-OPRT cells was 11 μM, which was lower than those of control cells (IC_{50}: 150 μM) (Figure 3).

4. Discussion

For decades, 5-FU and its derivatives such as 5′-DFUR and tegafur have been used to treat cancer patients, and the effectiveness of 5-FU is well proven in HNSCC. However, the presence of drug-resistant tumor cells, which occurs with other chemotherapeutic agents as well, causes poor response to 5-FU-based chemotherapy [3].
To phosphorylate 5-FU into its nucleotides, the following 3 metabolic pathways have been reported: pathway 1: phosphorylation to 5-fluorouridine monophosphate (FUMP) by OPRT; pathway 2: phosphorylation to 5-fluorodeoxyuridine (FdUR) by TP and a sequent conversion to 5-fluorodeoxyuridine-monophosphate (FdUMP) by thymidine kinase (TK); pathway 3: phosphorylation to 5-fluroouridine (FUR) by UP and a sequent conversion to FUMP by uridine kinase (UK) [9, 10]. Thus, OPRT is one of the main enzymes responsible for the phosphorylation of 5-FU in human cancer cells. In addition, several clinical reports have demonstrated a relationship between OPRT activity and 5-FU sensitivity in HNSCC. This relationship suggests that OPRT expression may affect the sensitivity to 5-FU treatment.

In conclusion, our data suggest that OPRT affects the chemotherapeutic effect of 5-FU in HNSCC cells in vitro. The present results strongly indicate that OPRT overexpression plays an important role in the sensitivity of HNSCC to 5-FU chemotherapy. Because the level of OPRT expression could be used as a predictive indicator for 5-FU efficacy against HNSCC, the accurate prediction of 5-FU efficacy may help to select patients for more intensive treatment including CDDP based chemoradiotherapy.

Conflict of Interests

The authors declare no conflict of interests.

References

[1] G. Nishimura, M. Tsukuda, C. Horiuchi et al., “Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas,” *Auris Nasus Larynx*, vol. 34, no. 4, pp. 499–504, 2007.

[2] C. G. Moertel, “Chemotherapy for colorectal cancer,” *The New England Journal of Medicine*, vol. 330, no. 16, pp. 1136–1142, 1994.

[3] D. B. Longley, D. P. Harkin, and P. G. Johnston, “5-Fluorouracil: mechanisms of action and clinical strategies,” *Nature Reviews Cancer*, vol. 3, no. 5, pp. 330–338, 2003.

[4] T. Aomoto et al., “OPRT overexpression plays an important role in the increased sensitivity of gastric carcinomas to 5-FU chemotherapy,” *J. Clin. Oncol.*, vol. 22, no. 9, pp. 1585–1592, 2004.

[5] Inaba et al., “OPRT activity in the 5-FU-resistant cell line,” *Cancer Res.*, vol. 55, no. 18, pp. 4347–4351, 1995.

[6] Miyake et al., “OPRT may play a potential role in regulating the malignant potential of pancreatic cancer,” *J. Clin. Oncol.*, vol. 22, no. 11, pp. 2078–2084, 2004.

[7] Regulation of OPRT expression and its involvement with tumor proliferation remains unclear, we could not reach any conclusion about the relationship between this enzyme and tumor progression.

[8] In conclusion, our data suggest that OPRT affects the chemotherapeutic effect of 5-FU in HNSCC cells in vitro. The present results strongly indicate that OPRT overexpression plays an important role in the sensitivity of HNSCC to 5-FU chemotherapy. Because the level of OPRT expression could be used as a predictive indicator for 5-FU efficacy against HNSCC, the accurate prediction of 5-FU efficacy may help to select patients for more intensive treatment including CDDP based chemoradiotherapy.
[4] J. Taomoto, K. Yoshida, Y. Wada et al., “Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines,” *Oncology*, vol. 70, no. 6, pp. 458–464, 2007.

[5] R. Fujii, A. Seshimo, and S. Kameoka, “Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma,” *International Journal of Clinical Oncology*, vol. 8, no. 2, pp. 72–78, 2003.

[6] W. Ichikawa, H. Uetake, Y. Shirotta et al., “Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer,” *British Journal of Cancer*, vol. 89, no. 8, pp. 1486–1492, 2003.

[7] R. Yasumatsu, T. Nakashima, H. Uryu et al., “The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells,” *Oral Oncology*, vol. 45, no. 2, pp. 141–147, 2009.

[8] R. Yasumatsu, T. Nakashima, H. Uryu et al., “Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma,” *Chemotherapy*, vol. 55, no. 1, pp. 36–41, 2008.

[9] G. J. Peters, E. Laurensse, and A. Leyva, “Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes,” *Cancer Research*, vol. 46, no. 1, pp. 20–28, 1986.

[10] G. J. Peters, C. J. Van Groeningen, E. J. Laurensse, and H. M. Pinedo, “A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa,” *Cancer*, vol. 68, no. 9, pp. 1903–1909, 1991.

[11] M. Inaba, J. Mitsuihashi, H. Sawada et al., “Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells,” *Japanese Journal of Cancer Research*, vol. 87, no. 2, pp. 212–220, 1996.

[12] Y. Mizutani, H. Wada, M. Fukushima et al., “Prognostic Significance of Orotate Phosphoribosyltransferase Activity in Bladder Carcinoma,” *Cancer*, vol. 100, no. 4, pp. 723–731, 2004.

[13] K. Miyake, S. Imura, T. Yoshizumi, T. Ikemoto, Y. Morine, and M. Shimada, “Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer,” *International Journal of Clinical Oncology*, vol. 12, no. 2, pp. 111–119, 2007.